Sugi Predict

Sugi Predict / Compounds / SCHEMBL6662392

SCHEMBL6662392

SCHEMBL6662392

CC(=O)Nc1[c]c2ccccc2cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSD17B10 Q99714 2/20 0.42
▸ NAPRT Q6XQN6 1/20 0.42
▸ KDM4E B2RXH2 5/20 0.40
▸ ALDH1A1 P00352 5/20 0.40
▸ HPGD P15428 3/20 0.40
▸ MAPT P10636 3/20 0.40
▸ HSP90AA1 P07900 1/20 0.40
▸ HSP90AB1 P08238 1/20 0.40
▸ ADORA1 P30542 2/20 0.39
▸ DYRK1A Q13627 1/20 0.39
▸ NPC1 O15118 3/20 0.38
▸ RAB9A P51151 3/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ TAAR1 Q96RJ0 1/20 0.38
▸ POLB P06746 1/20 0.38
▸ ABCC9 O60706 1/20 0.38
▸ ABCC8 Q09428 1/20 0.38
▸ KCNJ11 Q14654 1/20 0.38
▸ KCNJ8 Q15842 1/20 0.38
▸ LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL299990 0.77 NPC1 (0.51) HSD17B10KDM4EALDH1A1HPGDADORA1
SCHEMBL2245451 0.75 NCF1 (0.38) —
SCHEMBL9637938 0.75 IDO1 (0.32) —
SCHEMBL9785261 0.74 SMN1; SMN2 (0.51) HSD17B10NAPRTKDM4EALDH1A1HPGD
SCHEMBL2161029 0.74 HSD17B10 (0.48) HSD17B10NAPRTKDM4EALDH1A1HPGD
SCHEMBL758982 0.72 ALDH1A1 (0.38) KDM4EALDH1A1HPGDMAPTNPC1
SCHEMBL5961725 0.71 KEAP1 (0.43) NPC1RAB9AKMT2AL3MBTL1
SCHEMBL4723785 0.70 MEN1 (0.33) HSD17B10ALDH1A1MAPTNPC1RAB9A
SCHEMBL8877645 0.70 ALDH1A1 (0.39) ALDH1A1
SCHEMBL27466799 0.70 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1200457-B1 CYSTEINE PROTEASE INHIBITORS NAEJA PHARMACEUTICAL INC (CA) 2004-08-25 — — EP claimed
US-20040024000-A1 Dihydropyrimidine derivatives as cysteine protease inhibitors NAEJA PHARMACEUTICAL INC. (CA) 2004-02-05 — — US claimed
US-6635621-B1 Alpha amino acid amide derivatives; reducing cathepsins B, L, S and/or K activity NAEJA PHARMACEUTICAL INC. (CA) 2003-10-21 — — US claimed
EP-1326848-A1 DIHYDROPYRIMIDINE DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS Naeja Pharmaceutical Inc. (CA) 2003-07-16 — — EP claimed
US-6569847-B1 Inhibitors of cathepsins for treating muscular dystrophy, osteoporosis, rheumatoid arthritis, neuronal or cardiac ischaemia, allergy, or Chagas disease NAEJA PHARMACEUTICALS INC. (CA) 2003-05-27 — — US claimed
JP-2002544121-A — — 2002-12-24 — — JP claimed
EP-1200457-A2 CYSTEINE PROTEASE INHIBITORS Naeja Pharmaceutical Inc. (CA) 2002-05-02 — — EP claimed
WO-2002032879-A1 DIHYDROPYRIMIDINE DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS NAEJA PHARMACEUTICAL INC. (CA) 2002-04-25 — — WO claimed
EP-1165506-A1 SUBSTITUTED AZETIDIN-2-ONES AS CYSTEINE PROTEASE INHIBITORS Naeja Pharmaceutical Inc. (CA) 2002-01-02 — — EP claimed
WO-2001009169-A2 CYSTEINE PROTEASE INHIBITORS NAEJA PHARMACEUTICAL INC (CA) 2001-02-08 — — WO claimed
WO-2000059881-A1 SUBSTITUTED AZETIDIN-2-ONES AS CYSTEINE PROTEASE INHIBITORS NAEJA PHARMACEUTICAL INC (CA) 2000-10-12 — — WO claimed
US-4659360-A HERBICIDES FMC CORPORATION (US) 1987-04-21 — — US claimed
US-20220024891-A1 THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM 2022-01-27 — — US disclosed
EP-3890715-A1 THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER The Board Of Regents Of The University Of Texas System (US) 2021-10-13 — — EP disclosed
WO-2020117972-A1 THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) 2020-06-11 — — WO disclosed
EP-1200457-B1 CYSTEINE PROTEASE INHIBITORS NAEJA PHARMACEUTICAL INC (CA) 2004-08-25 — — EP disclosed
WO-2001051469-A1 PIPERIDINE AND PIPERAZINE DERIVATIVES WHICH FUNCTION AS 5-HT2A RECEPTOR ANTAGONISTS MERCK PATENT GMBH (DE) 2001-07-19 — — WO disclosed
WO-2001009169-A2 CYSTEINE PROTEASE INHIBITORS NAEJA PHARMACEUTICAL INC (CA) 2001-02-08 — — WO disclosed
WO-2000059881-A1 SUBSTITUTED AZETIDIN-2-ONES AS CYSTEINE PROTEASE INHIBITORS NAEJA PHARMACEUTICAL INC (CA) 2000-10-12 — — WO disclosed
WO-1999048911-A1 MONOBACTAM ENZYME INHIBITORS NAEJA PHARMACEUTICAL INC. (GB) 1999-09-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220024891-A1 THERAPEUTICS TARGETING MUTANT ADENOMATOUS POLYPOSIS COLI (APC) FOR THE TREATMENT OF CANCER APC, VHL, KRAS HSD17B10 1870/4885NAPRT 2842/4885KDM4E 1361/4885
US-20040024000-A1 Dihydropyrimidine derivatives as cysteine protease inhibitors DPEP1, DNPEP, PEPD HSD17B10 2359/4885NAPRT 1342/4885KDM4E 3705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.